Investors in Scientific

SIFEM is the Swiss Development Finance Institution (DFI). It is owned by the Swiss Government and an integral part of Switzerland's International Cooperation Strategy. SIFEM provides long-term financing through financial intermediaries to SMEs and other fast-growing companies in developing countries. It aims to reduce poverty and foster sustainable, inclusive and resilient economies by creating and securing more and better jobs, growing opportunities for the underserved and supporting projects towards a Just Transition. SIFEM aligns its investments with international environmental goals to address the global climate crisis and support emerging markets in achieving low-carbon economic growth. With its investments it contributes to closing financing gaps and mobilising additional private capital for the growth of local companies in developing countries. By the end of 2022, SIFEM's investment portfolio amounts to USD 451m, thereby financing directly and indirectly 612 companies in 80 countries. Since its inception, SIFEM made commitments of almost USD 1.3 billion.

Kathaka is a London-based single-family office that specializes in venture capital and philanthropy. With a dual focus on investing in innovative startups and supporting philanthropic initiatives, Kathaka aims to drive positive change and create lasting impact. They provide strategic capital and guidance to early-stage ventures while also dedicating resources to charitable causes, fostering a balanced approach to growth and giving back.

K4 Group AS is a Norwegian family-owned investment company founded in 2016. They invest in various sectors, including FMCG, Seafood, Property, Healthcare, and Industrial Technology, aiming to preserve wealth and leave a positive footprint.

HS LifeSciences was established in 2008 by seasoned biotech entrepreneurs with many years of experience in managing biotech companies. The lessons learned over the years have been distilled into a new business model centered on the foundation and growth of new life sciences companies without the need for conventional multiple rounds of equity-based financing.